AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital
Summary
"We are delighted to strengthen AffyImmunes relationship with ORI with this additional financing," said AffyImmune President & COO Eric von Hofe, Ph.D. "ORIs dedication to transformative science and deep industry knowledge have been invaluable to our company strategy and growth, and their latest investment highlights the potential of our cutting-edge Tune & Track platform to revolutionize the treatment of solid tumors across a variety of cancers." "Were excited to further our investment in AffyImmune, as existing CAR T therapies have not been able to treat solid tumors or have only been effective in a small number of solid cancer patients," said Simone Song, Founder and Senior Partner at ORI Capital and Chairperson of AffyImmunes Board of Directors. "AffyImmune is advancing a leading pipeline of affinity-tuned CAR T therapies to treat solid tumors based on its Tune and Track technology platform, and I look forward to working with their management team and Board," said Ms. Yang. The company was founded in 2016 and began enrolling patients in its Phase 1 trial to treat advanced thyroid cancer in 2020. Its self-developed artificial intelligence (AI) research system, ORIzon, provides daily updates on 15,000+ companies around the world, follows 2,000+ key opinion leaders, and tracks the investment activities of 1,000+ fund managers.